Skip to content
Award Badge 1
Award Badge 2
All posts

Introducing HCP-Patient Conversations on Ferma

HCP-P on Ferma

See what doctors and patients actually say about a therapy, right next to the pipeline, trial and deal analysis Ferma already produces.

Today we are adding HCP-Patient Conversations to Ferma. When an agent builds a competitive landscape, an indication landscape, or a view of unmet need, it can now include a section on how doctors and patients talk about the therapies in that market, in their own words, with every quote tied to a real recorded visit.

Ferma already brings pipelines, trials, publications, conferences, news and deals into one place and returns a finished, cited deliverable in minutes. HCP-Patient Conversations adds something teams have found hard to reach before: the real conversations behind the data, drawn from ZoomRx's primary research with physicians and patients.

It works inside the agents you already use. There is nothing separate to run. When an agent builds a landscape, a target product profile, a valuation or a read on unmet need, and the disease has recorded conversations, it offers to add this section and folds it into the same cited deliverable. You stay in one workflow, and the voice of the clinic sits right beside the evidence the agent already pulled.

What you can see

The conversations sit next to the evidence, so you can move from what the data shows to what people in the clinic actually say. In practice, teams use it to see:

  • The themes doctors and patients raise about each therapy, with representative quotes and the month they were said.
  • How patients were treated before, and what the doctor prescribed during the visit.
  • How often each therapy comes up across the conversations in a market.

Because the conversations come from real visits, the capability is richest for therapies doctors are actively prescribing today. Where a disease has no recorded conversations, the agent leaves the section out instead of showing an empty one.

How different teams use it

  • Medical Affairs can see how physicians explain a therapy to patients, including side effects, cost and staying on treatment, which points to where education is most needed.
  • Competitive Intelligence can hear how doctors choose between competing therapies and what moves them to switch.
  • Valuation and forecasting teams can ground their market share assumptions in real visits.
  • Search & Evaluation and New Product Planning teams can read the market a new asset would enter: what patients are on today, the unmet need, and the barriers doctors describe.

Examples

We built a few example agents that show the capability across these use cases. You can explore each one below:

  • Obesity & GLP-1 Therapies: HCP-Patient Conversation Insights, for Medical Affairs
  • Plaque Psoriasis: Competitive Landscape with HCP-Patient Insights, for Competitive Intelligence
  • Generalized Myasthenia Gravis: rNPV Valuation, for valuation
  • Atopic Dermatitis: Treatment Landscape and Switching Dynamics, for Search & Evaluation
  • Chronic Spontaneous Urticaria: Target Product Profile, for Business Development & Licensing

 

 

Getting access

HCP-Patient Conversations is available now. Reach out to us for access, and we would be happy to walk your team through it and set up a free trial.

 

Get in Touch